首页> 外文期刊>BMC Nephrology >Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study
【24h】

Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study

机译:一项回顾性研究表明,C4水平升高和C3水平降低与免疫球蛋白A肾病患者预后不良有关

获取原文
           

摘要

Background An association between serum complement levels and poor renal prognosis in patients with immunoglobulin A nephropathy (IgAN) remains controversial. Methods We conducted a retrospective study examining the relationship between serum complement levels and prognosis in patients with IgAN. Between 2009 and 2013, patients with biopsy-confirmed IgAN were identified from the Second Affiliated Hospital of Wenzhou Medical College, China, and various parameters were documented during follow-up until 2015. The definition of the primary endpoint was a decrease of estimated glomerular filtration rate (eGFR) more than 30% from their baseline levels. Results A total of 403 patients (55.3% female, average 33.7?months of follow-up) were identified and enrolled, with the primary endpoint occurring in 39 (9.8%) patients. Among the patients selected, 202 (50.1%) received corticosteroid treatment alone or in combination with another immunosuppressant (GS group), while others did not receive immunosuppressive treatment (non-GS group). The incidence of the primary endpoint was slightly lower in the GS group compared to the non-GS group (7.0% versus 12.6%, p =?0.06). Multivariate Cox proportional-hazard regression analyses, adjusting for age, systolic and diastolic blood pressure, 24-h urine protein, and immunosuppressive therapy, showed that serum complement 4 (C4) levels (hazard ratio [HR] 2.4, 95% confidence interval [CI] 1.6-3.8, p p Conclusions We demonstrated that an increase in serum C4, as well as a decrease in C3, was an important outcome determinant for patients with IgAN. Testing serum C3 and C4 levels might assist in predicting renal outcomes among these patients.
机译:背景免疫球蛋白A肾病(IgAN)患者的血清补体水平与不良肾预后之间的关联仍存在争议。方法我们进行了一项回顾性研究,检查了IgAN患者血清补体水平与预后之间的关系。在2009年至2013年间,从中国温州医学院附属第二医院确定了活检确诊的IgAN患者,并在随访至2015年期间记录了各种参数。主要终点的定义是估计的肾小球滤过率降低率(eGFR)超出其基线水平的30%以上。结果共有403例患者(女性55.3%,平均33.7个月的随访)被纳入研究,主要终点发生在39例患者中(9.8%)。在所选择的患者中,有202名(50.1%)单独或与另一种免疫抑制剂联合接受了皮质类固醇治疗(GS组),而其他人未接受免疫抑制治疗(非GS组)。与非GS组相比,GS组的主要终点发生率略低(7.0%比12.6%,p =?0.06)。多元Cox比例风险回归分析,针对年龄,收缩压和舒张压,24小时尿蛋白和免疫抑制疗法进行了调整,结果显示血清补体4(C4)水平(风险比[HR] 2.4、95%置信区间[ CI] 1.6-3.8,pp结论我们证明,血清C4的升高和C3的降低是IgAN患者重要的结局决定因素,测试血清C3和C4水平可能有助于预测这些患者的肾结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号